Browsing Tag
Mereo BioPharma Group plc
4 posts
Ultragenyx Pharmaceutical faces shareholder litigation risks after Orbit study update triggers stock plunge
Ultragenyx faces legal probe and investor scrutiny after a 25% stock drop tied to delayed Phase 3 Orbit study data for UX143. Learn what analysts expect next.
Is Mereo BioPharma now a hidden EU rare disease play with Ultragenyx exposure?
Mereo BioPharma holds EU and UK rights to setrusumab. Can upcoming Phase 3 data make it a hidden rare disease winner in 2025?
Can final-year OI data rescue Ultragenyx’s $245M pipeline gamble on setrusumab?
Ultragenyx’s setrusumab trial didn’t stop early—but can final data still unlock $245M in milestones and rescue biotech investor confidence?
Ultragenyx stock plummets 25% after Phase 3 OI trial continues without early stop
Ultragenyx stock plunged 25% as the UX143 Phase 3 trial for osteogenesis imperfecta proceeds without early stop. Find out what this means for investors.